Table 1. Baseline characteristics of the CHC patients before anti-HCV treatment.

	G1(n = 118)	G2(n = 111)	Student’s t-test or chi-squared P values
Male (%)	70 (63.63%)	56 (52.33%)	0.475
Age (yr)#	53.1+/−12.6	55.0+/−11.8	0.251
BMI	24.0+/−3.4	24.9+/−3.4	0.072
HCV RNA (millionIU/ml)	5.1+/−8.3	1.5+/−2.3	<0.001*
Log HCVRNA (IU/ml)	6.10+/−0.98	5.90+/−0.92	0.049*
HCV core Ag (fmol/L)	7643.5+/−6965.2	3497.7+/−3879.4	0.002*
IL-28B rs12979860 CC/CT+TT, n(CC%)#	103/15(87.3%)	104/7(93.6%)	0.595
ALT (U/L)	100.6+/−79.3	112.5+/−82.7	0.354
Fatty liver#	52 (44%)	53 (48%)	0.881
APRI	1.53+/−2.2	1.42+/−1.66	0.817
TG (mg/dL)	108.4+/−59.	99.9+/−44.8	0.259
TC (mg/dL)	170.5+/−32.0	166.9+/−32.2	0.417
HDL (mg/dL)	48.8+/−15.6	48.9+/13.2	0.946
LDL (mg/dL)	103.6+/−40.8	100.5+/−26.1	0.53
TG/HDL	2.62+/−2.35	2.22+/−1.40	0.151
Apo AI (g/L)	1.57+/−1.09	1.38+/−0.25	0.166
Apo B (g/L)	0.83+/−0.20	0.81+/−0.19	0.651
Glucose (AC) (mg/dL)	100.8+/−33.0	100.7+/−29.9	0.990
Insulin (µIU/mL)	14.19+/−22.34	10.61+/−10.34	0.2
C-peptide (ng/mL)	2.93+/−3.02	2.76+/−2.09	0.712
Hb-A1c (%; mmol/mol)	5.90+/−1.02; 41+/−11	5.75+/−0.75; 39.5+/−8.5	0.317
HOMA-IR	4.25+/−10.33	2.67+/−3.01	0.19
SVR (%)#	90 (77.5%)	100 (91.7%)	0.005*

^#chi-squared test;

*p<0.05.